Portfolio Risk
Cash runway vs days to next catalyst — spot binary event risk at a glance
| Company | Catalyst | Type | Days | Runway | Impact | Confidence |
|---|---|---|---|---|---|---|
| NEU | NNZ-2591 Phase 2 Phelan-McDermid interim | Data Readout | 5d | CF+ | high | expected |
| CHM | CLTX CAR-T Phase 1 GBM safety data | Data Readout | 5d | 2mo | high | expected |
| OSL | FDA HDE Application Review Decision | Regulatory | 21d | CF+ | high | expected |
| PME | FY2026 full-year results | Other | 24d | CF+ | high | confirmed |
| SHL | FY2026 full-year results | Other | 25d | CF+ | medium | confirmed |
| GTG | Outstanding periodic reports due | Regulatory | 34d | 0mo | high | confirmed |
| PNV | NovoSorb MTX hernia trial update | Data Readout | 36d | CF+ | medium | expected |
| HLS | FY2026 EBIT target test (~$48M) | Other | 36d | 0mo | high | expected |
| CYC | University Hospitals Cleveland 11-site Technegas deployment completion | Commercial | 36d | CF+ | high | expected |
| FPH | Trial data readout — High Flow Nasal Cannula Compared to Standard Oxygen for Endoscopic Ultrasound | Data Readout | 37d | CF+ | medium | speculative |
| NOX | Pre-IND meeting with US FDA for SOF-SKN™ | Regulatory | 42d | 1mo | high | expected |
| TLX | TLX101-Px (Pixclara) FDA PDUFA Decision | Regulatory | 47d | CF+ | high | confirmed |
| CU6 | AMPLIFY Phase 3 topline data | Data Readout | 66d | 27mo | high | expected |
| CSL | Garadacimab FDA filing decision | Regulatory | 66d | CF+ | high | expected |
| MSB | CHF Phase 3 interim data | Data Readout | 66d | 24mo | high | expected |
| SPL | DEP cabazitaxel Phase 2 update | Data Readout | 66d | 10mo | medium | expected |
| IMM | IMP761 Phase I MAD completion | Data Readout | 66d | CF+ | high | expected |
| AVH | PermeaDerm I study data readout | Data Readout | 66d | CF+ | medium | expected |
| AVR | Medtronic co-commercialization agreement details | partnership | 66d | 1mo | high | expected |
| 1AD | BZDS1901 first manufacturing runs in Australia | Commercial | 66d | 1mo | high | expected |
| 1AD | BZDS1901 FDA pre-IND meeting | Regulatory | 66d | 1mo | high | expected |
| SNT | SNT-4728 Phase 2 iRBD full results including digital and biological markers | Data Readout | 66d | 17mo | high | expected |
| COH | Nucleus Nexa System global rollout | Commercial | 66d | CF+ | medium | expected |
| PME | First digital pathology client deployment | Commercial | 66d | CF+ | high | expected |
| ILA | ISLA-101 end of Phase 2 meeting with FDA | Regulatory | 66d | 32mo | high | expected |
| IIQ | US CLIA laboratory partner announcement | partnership | 66d | 11mo | high | speculative |
| PAB | RLS-2202 Phase 1A first participant dosing | Regulatory | 66d | 13mo | high | expected |
| PAR | PARA_OA_012 Phase 3 Interim Analysis Results | Data Readout | 66d | 3mo | high | expected |
| NYR | PROTECT-MI recruitment acceleration | Commercial | 66d | 23mo | medium | expected |
| CSL | PHASE2 data readout — Zemaira Eosinophilic Esophagitis Pilot Study | Data Readout | 67d | CF+ | medium | speculative |
| ACW | PHASE2/PHASE3 data readout — Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease | Data Readout | 67d | 3mo | medium | speculative |
| RMD | Trial data readout — Exploration of Current and New Technologies for Accuracy of Diagnosing OSA | Data Readout | 67d | CF+ | medium | speculative |